|
|
| (7 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
| {{#seo:
| | #REDIRECT [[Clinical Trials Mesothelioma]] |
| |title=Mesothelioma Clinical Trials 2026: 53 Active Trials, CAR-T, TEAD Inhibitors
| |
| |description=Complete guide to 53 actively recruiting mesothelioma clinical trials in January 2026. CAR-T achieving 83% survival, first Phase III TEAD inhibitor, eligibility requirements.
| |
| |keywords=mesothelioma clinical trials, CAR-T cell therapy mesothelioma, TEAD inhibitor mesothelioma, VT3989, ISM6331, mesothelioma immunotherapy trials, mesothelioma treatment research
| |
| |image=Clinical-trials-mesothelioma.jpg
| |
| |author=Anna Jackson, Client Advocate, Danziger & De Llano
| |
| |published_time=2026-01-13
| |
| }}
| |
| | |
| {| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; background:#ffffff; border-radius:8px; overflow:hidden;"
| |
| |-
| |
| ! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" | 🔬 Clinical Trials Quick Facts
| |
| |-
| |
| | colspan="2" style="background:#e8f4f8; padding:10px; text-align:center; font-style:italic;" | January 2026 Trial Landscape
| |
| |-
| |
| | style="padding:10px; font-weight:bold; width:40%; background:#f8f9fa; border-bottom:1px solid #dee2e6;" | Active US Trials
| |
| | style="padding:10px; border-bottom:1px solid #dee2e6;" | 53 Recruiting
| |
| |-
| |
| | style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6;" | Patient Participation
| |
| | style="padding:10px; border-bottom:1px solid #dee2e6;" | Only 8%
| |
| |-
| |
| | style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6;" | CAR-T 1-Year Survival
| |
| | style="padding:10px; border-bottom:1px solid #dee2e6;" | 83%
| |
| |-
| |
| | style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6;" | Best Response Rate
| |
| | style="padding:10px; border-bottom:1px solid #dee2e6;" | 51.6% (BNT327)
| |
| |-
| |
| | style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6;" | Phase III Opening
| |
| | style="padding:10px; border-bottom:1px solid #dee2e6;" | H1 2026 (VT3989)
| |
| |-
| |
| | style="padding:10px; font-weight:bold; background:#f8f9fa;" | New US Cases/Year
| |
| | style="padding:10px;" | ~3,000
| |
| |-
| |
| | colspan="2" style="background:#1a5276; padding:10px; text-align:center;" | [https://dandell.com/contact-us/ <span style="color:white; font-weight:bold;">🛡️ Free Case Review →</span>]
| |
| |}
| |
| | |
| '''Mesothelioma Clinical Trials''' represent the cutting edge of treatment research, offering patients access to breakthrough therapies before they become widely available. As of January 2026, fifty-three mesothelioma clinical trials are actively recruiting patients across the United States, including revolutionary CAR-T cell therapies achieving 83% one-year survival, the first-ever Phase III trial of a TEAD inhibitor, and AI-designed drugs now in human testing.<ref>[https://www.cancer.gov/types/mesothelioma/patient/mesothelioma-treatment-pdq Mesothelioma Treatment (PDQ)], National Cancer Institute</ref>
| |
| | |
| == Executive Summary ==
| |
| | |
| The mesothelioma clinical trial landscape has transformed dramatically, yet patient participation remains critically low at just 8%—a significant drop from 14% in 2023.<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma/ Mesothelioma Overview], Mesothelioma Lawyer Center</ref> This gap exists despite proven survival benefits from trial participation. According to the National Cancer Institute, clinical trials are research studies that test new treatments and are essential to advancing cancer care.<ref>[https://www.cancer.gov/about-cancer/treatment/clinical-trials/what-are-trials What Are Clinical Trials?], National Cancer Institute</ref> In January 2026, patients have access to immunotherapy combinations extending median survival beyond 18 months, targeted therapies achieving 32% response rates in previously untreatable disease, and cellular therapies demonstrating unprecedented durability. The FDA approved pembrolizumab plus chemotherapy in September 2024 as a new first-line standard, with subcutaneous Keytruda QLEX following in January 2026.<ref>[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-pemetrexed-and-platinum-chemotherapy-malignant-pleural-mesothelioma FDA Approves Pembrolizumab for Mesothelioma], U.S. Food and Drug Administration</ref> VT3989, the first TEAD inhibitor, will advance to Phase III registration trials in the first half of 2026, representing a major milestone for targeted therapy in this disease. For patients and families navigating treatment decisions alongside legal compensation, specialized mesothelioma attorneys can help coordinate both processes simultaneously.<ref>[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis Guide], Danziger & De Llano</ref>
| |
| | |
| {| style="width:100%; background:#e8f4f8; border:2px solid #1a5276; border-radius:8px; margin:1em 0;"
| |
| |-
| |
| ! style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:left; border-radius:6px 6px 0 0;" | Key Facts: Mesothelioma Clinical Trials January 2026
| |
| |-
| |
| | style="padding:15px;" |
| |
| * '''53 actively recruiting''' mesothelioma clinical trials in the United States as of January 2026<ref>[https://clinicaltrials.gov/search?cond=Mesothelioma&aggFilters=status:rec Mesothelioma Clinical Trials - Recruiting], ClinicalTrials.gov</ref>
| |
| * '''8% patient participation rate'''—down from 14% in 2023 despite expanded options
| |
| * '''CAR-T cell therapy''' at Memorial Sloan Kettering achieves '''83% one-year survival'''
| |
| * '''VT3989 TEAD inhibitor''' advancing to Phase III in H1 2026 with 32% response rate
| |
| * '''ISM6331'''—first AI-designed mesothelioma drug—dosed first patient January 22, 2025
| |
| * '''Pembrolizumab + chemotherapy''' FDA approved September 2024; median survival 16.9 months
| |
| * '''Keytruda QLEX''' (subcutaneous) approved January 11, 2026 for all indications
| |
| * '''BNT327/PM8002''' achieves 51.6% overall response rate; 75% in peritoneal mesothelioma
| |
| * '''CheckMate 743''' shows 23.2% three-year survival with nivolumab plus ipilimumab
| |
| * '''Approximately 3,000 new US cases''' diagnosed annually according to SEER data<ref>[https://seer.cancer.gov/statfacts/html/meso.html Mesothelioma Cancer Stat Facts], National Cancer Institute SEER</ref>
| |
| |}
| |
| | |
| == What Phase III Trials Are Currently Recruiting? ==
| |
| | |
| Phase III trials represent the final stage before FDA approval and offer patients access to therapies that have already demonstrated efficacy in earlier studies.
| |
| | |
| === eVOLVE-Meso Trial (NCT06097728) ===
| |
| | |
| The eVOLVE-Meso trial is a Phase III, randomized, open-label, multicenter study testing volrustomig (MEDI5752), a novel PD-1/CTLA-4 bispecific antibody, in combination with carboplatin and pemetrexed.<ref>[https://clinicaltrials.gov/study/NCT06097728 A Phase 3 Study of Volrustomig in Unresectable Pleural Mesothelioma], ClinicalTrials.gov</ref>
| |
| | |
| '''Trial Specifications:'''
| |
| * '''Status:''' Actively recruiting globally
| |
| * '''Sponsor:''' AstraZeneca
| |
| * '''Enrollment Target:''' 825 patients worldwide
| |
| * '''Mechanism:''' PD-1/CTLA-4 bispecific antibody providing selective CTLA-4 blockade on activated T cells
| |
| * '''Comparator Arms:''' Platinum-based chemotherapy or nivolumab plus ipilimumab
| |
| * '''Eligibility:''' Unresectable pleural mesothelioma with no prior systemic therapy
| |
| * '''Locations:''' United States, Canada, Brazil, China, Europe, Japan
| |
| * '''Expected Completion:''' Data anticipated post-2026
| |
| | |
| === ATOMIC-Meso Results (Pegargiminase/ADI-PEG20) ===
| |
| | |
| The ATOMIC-Meso trial has completed, with practice-changing results published in JAMA Oncology in March 2024.<ref>[https://mesothelioma.net/mesothelioma-emerging-treatments-research/ New Mesothelioma Treatments and Research], Mesothelioma.net</ref>
| |
| | |
| '''Published Results (249 patients with non-epithelioid pleural mesothelioma):'''
| |
| * '''Median overall survival:''' 9.3 months versus 7.7 months with placebo plus chemotherapy
| |
| * '''Three-year survival:''' Quadrupled compared to placebo arm
| |
| * '''Progression-free survival:''' 6.2 months versus 5.6 months (HR 0.65; p=0.02)
| |
| * '''Risk reduction:''' 35% reduction in progression risk
| |
| * '''Mechanism:''' Arginine depletion therapy targeting ASS1-deficient tumors
| |
| | |
| {| style="width:90%; margin:1.5em auto; background:#f8f9fa; border-left:4px solid #1a5276; border-radius:0 4px 4px 0;"
| |
| |-
| |
| | style="padding:20px 25px 15px; font-style:italic; font-size:1.05em; line-height:1.6;" | "The ATOMIC-Meso results represent a breakthrough for patients with non-epithelioid mesothelioma, a subtype that historically had very limited treatment options. Quadrupling three-year survival changes the outlook for these patients and their families."
| |
| |-
| |
| | style="padding:5px 25px 20px; text-align:right;" | '''— Rod De Llano,''' Founding Partner, Danziger & De Llano
| |
| |}
| |
| | |
| == What CAR-T Cell Therapies Are Available for Mesothelioma? ==
| |
| | |
| CAR-T (Chimeric Antigen Receptor T-cell) therapy represents one of the most promising frontiers in mesothelioma treatment, with multiple trials demonstrating unprecedented survival outcomes.<ref>[https://www.cancer.gov/about-cancer/treatment/research/car-t-cells CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers], National Cancer Institute</ref>
| |
| | |
| === TNhYP218 Trial at National Cancer Institute (NCT06885697) ===
| |
| | |
| This Phase I dose-escalation study evaluates anti-mesothelin TNaive/SCM hYP218 CAR T cells, designed for enhanced tumor infiltration and persistence.<ref>[https://clinicaltrials.gov/study/NCT06885697 Anti-Mesothelin CAR T Cell Study], ClinicalTrials.gov</ref>
| |
| | |
| '''Trial Details:'''
| |
| * '''Status:''' Recruiting since 2025
| |
| * '''Location:''' National Cancer Institute, Bethesda, Maryland
| |
| * '''Innovation:''' Targets membrane-proximal epitope of mesothelin, showing 2-4 fold better tumor killing than membrane-distal approaches in preclinical studies
| |
| * '''Eligibility:''' Age 18 or older, mesothelin expression greater than 50% of tumor cells, ECOG 0-1
| |
| * '''Monitoring:''' Patients must remain within 2 hours of NIH for 30 days post-infusion
| |
| * '''Follow-up:''' 15 years per FDA requirement
| |
| | |
| === Memorial Sloan Kettering Intrapleural CAR-T Program (NCT04577326) ===
| |
| | |
| This groundbreaking program pioneered regional delivery of CAR-T cells directly into the pleural space, minimizing systemic toxicity while maximizing tumor contact.<ref>[https://clinicaltrials.gov/study/NCT04577326 Mesothelin-Targeted CAR T-Cells Administered Intrapleurally], ClinicalTrials.gov</ref>
| |
| | |
| {| style="width:100%; background:#d4edda; border:1px solid #28a745; border-left:5px solid #28a745; border-radius:4px; margin:1em 0;"
| |
| |-
| |
| | style="padding:15px; color:#155724;" | '''✓ Breakthrough Results:''' Memorial Sloan Kettering's intrapleural CAR-T program achieved '''83% one-year survival''' for malignant pleural mesothelioma patients—dramatically exceeding historical outcomes of 12-16 months median survival with standard therapy.
| |
| |}
| |
| | |
| '''Published Results:'''
| |
| * '''One-year survival:''' 83% for malignant pleural mesothelioma patients
| |
| * '''CAR-T persistence:''' Cells detected in peripheral blood for more than 100 days in 39% of patients
| |
| * '''Durable responses:''' One patient achieved partial response lasting 26 months
| |
| * '''Safety profile:''' Intrapleural administration was safe and well tolerated
| |
| * '''Combination approach:''' 18 patients received CAR-T with pembrolizumab, demonstrating enhanced function
| |
| | |
| === SynKIR-110 Trial (STAR-101, NCT05568680) ===
| |
| | |
| This novel approach uses KIR-CAR T cells targeting mesothelin across multiple tumor types including mesothelioma.<ref>[https://clinicaltrials.gov/study/NCT05568680 SynKIR-110 in Mesothelin-Expressing Solid Tumors], ClinicalTrials.gov</ref>
| |
| | |
| * '''Status:''' Completed enrollment of Cohorts 1-3 without dose-limiting toxicities as of May 2025
| |
| * '''Sites:''' Multiple US locations including Penn Medicine
| |
| * '''Safety:''' No dose-limiting toxicities in completed cohorts
| |
| | |
| == What Targeted Therapies Are Showing Promise? ==
| |
| | |
| === VT3989 TEAD Inhibitor — Advancing to Phase III ===
| |
| | |
| VT3989 represents a breakthrough in targeting the previously "undruggable" Hippo/YAP/TEAD pathway, which is dysregulated in the majority of mesotheliomas.<ref>[https://mesotheliomaattorney.com/mesothelioma/treatment/new/ New Mesothelioma Treatments], MesotheliomaAttorney.com</ref>
| |
| | |
| '''ESMO 2025 Results (Published Nature Medicine December 2025):'''
| |
| * '''Objective response rate:''' 32% in 22 mesothelioma patients at optimized dose
| |
| * '''Disease control rate:''' 86% when incorporating optimal dose and UACR threshold
| |
| * '''Median progression-free survival:''' 10 months
| |
| * '''Duration of response:''' 8 patients on treatment more than 1 year; one approaching 2 years
| |
| * '''Selected dose:''' 100 mg two-weeks-on/two-weeks-off for Phase III
| |
| * '''Safety:''' Favorable profile with mostly grade 1-2 toxicities; proteinuria reversible with dose adjustment
| |
| * '''Tumor types:''' Activity demonstrated in both NF2-mutant and wild-type tumors
| |
| | |
| '''Regulatory Designations:'''
| |
| * FDA Orphan Drug Designation<ref>[https://www.accessdata.fda.gov/scripts/opdlisting/oopd/ FDA Orphan Drug Product Designation Database], U.S. Food and Drug Administration</ref>
| |
| * FDA Fast Track Designation
| |
| | |
| {| style="width:100%; background:#cce5ff; border:1px solid #007bff; border-left:5px solid #007bff; border-radius:4px; margin:1em 0;"
| |
| |-
| |
| | style="padding:15px; color:#004085;" | '''ℹ️ Historic Milestone:''' VT3989 will become the '''first TEAD inhibitor to reach a registrational Phase III trial''' in mesothelioma when it opens in the first half of 2026, representing a major advance for targeted therapy in this disease.
| |
| |}
| |
| | |
| === ISM6331 — First AI-Designed Drug for Mesothelioma (NCT06566079) ===
| |
| | |
| This pan-TEAD inhibitor was designed using Insilico Medicine's Chemistry42 AI platform, representing the first AI-designed drug to enter clinical testing for mesothelioma.<ref>[https://clinicaltrials.gov/study/NCT06566079 ISM6331 in Advanced Solid Tumors], ClinicalTrials.gov</ref>
| |
| | |
| '''Development Timeline:'''
| |
| * '''September 2020:''' AI platform launched
| |
| * '''June 2023:''' Recommended for preclinical studies
| |
| * '''April 2024:''' AACR presentation showing broad cancer-killing effects
| |
| * '''June 2024:''' FDA Orphan Drug Designation granted
| |
| * '''August 2024:''' IND clearance received
| |
| * '''January 22, 2025:''' First patient dosed in China
| |
| * '''2026:''' US enrollment expected
| |
| | |
| '''Mechanism:''' Pan-TEAD inhibitor blocking the palmitoylation site, disrupting YAP/TAZ-TEAD transcriptional activity
| |
| | |
| === IAG933 TEAD Inhibitor — Development Discontinued ===
| |
| | |
| Novartis discontinued development of IAG933 in October 2025 following underwhelming ESMO 2025 data showing only 13% objective response rate in 30 pleural mesothelioma patients. QTc prolongation dose-limiting toxicities in 4 patients contributed to the decision.<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma/diagnosis/ Mesothelioma Diagnosis], Mesothelioma Lawyer Center</ref>
| |
| | |
| == What Are the Latest Immunotherapy Results? ==
| |
| | |
| === Pembrolizumab Plus Chemotherapy — FDA Approved September 2024 ===
| |
| | |
| The KEYNOTE-483 trial led to FDA approval for first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma on September 17, 2024.<ref>[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-pemetrexed-and-platinum-chemotherapy-malignant-pleural-mesothelioma FDA Approves Pembrolizumab for Mesothelioma], U.S. Food and Drug Administration</ref>
| |
| | |
| '''Trial Results:'''
| |
| * '''Median overall survival:''' 16.9 months versus 14.1 months with chemotherapy alone
| |
| * '''Hazard ratio:''' 0.79 (95% CI: 0.63-0.99; p=0.0209)
| |
| * '''Confirmed objective response rate:''' 52% versus 29%
| |
| * '''Median duration of response:''' 6.9 versus 6.8 months
| |
| * '''Regimen:''' Pembrolizumab with pemetrexed and platinum chemotherapy
| |
| | |
| '''January 2026 Update:''' FDA approved Keytruda QLEX (subcutaneous pembrolizumab) on January 11, 2026, offering a 1-minute injection every 3 weeks as an alternative to IV infusion for all 38 pembrolizumab indications including mesothelioma.
| |
| | |
| === Nivolumab Plus Ipilimumab — CheckMate 743 Long-term Data ===
| |
| | |
| CheckMate 743 remains the only Phase 3 trial demonstrating survival improvement sustained over 3 years with first-line immunotherapy in unresectable malignant pleural mesothelioma.<ref>[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-and-ipilimumab-unresectable-malignant-pleural-mesothelioma FDA Approves Nivolumab and Ipilimumab for Mesothelioma], U.S. Food and Drug Administration</ref>
| |
| | |
| '''Three-Year Follow-up Results:'''
| |
| * '''Three-year overall survival:''' 23.2% versus 15.4% with chemotherapy
| |
| * '''Sustained benefit:''' Observed regardless of histology
| |
| * '''Duration of response:''' Longer with dual immunotherapy at 3 years
| |
| * '''Safety:''' Consistent profile with no new signals at long-term follow-up
| |
| | |
| {| style="width:90%; margin:1.5em auto; background:#f8f9fa; border-left:4px solid #1a5276; border-radius:0 4px 4px 0;"
| |
| |-
| |
| | style="padding:20px 25px 15px; font-style:italic; font-size:1.05em; line-height:1.6;" | "Clinical trials represent the cutting edge of mesothelioma treatment. We encourage every patient to explore trial options because tomorrow's standard treatments are available today through these programs. The survival improvements we're seeing with newer therapies are remarkable."
| |
| |-
| |
| | style="padding:5px 25px 20px; text-align:right;" | '''— Paul Danziger,''' Founding Partner, Danziger & De Llano
| |
| |}
| |
| | |
| === BNT327/PM8002 — Exceptional Peritoneal Mesothelioma Results ===
| |
| | |
| This PD-L1/VEGF-A bispecific antibody demonstrated remarkable activity at ASCO 2025, particularly in peritoneal mesothelioma.<ref>[https://mesotheliomaattorney.com/mesothelioma/types/peritoneal/ Peritoneal Mesothelioma], MesotheliomaAttorney.com</ref>
| |
| | |
| '''Phase 2 Trial Results (31 patients with unresectable mesothelioma):'''
| |
| * '''Confirmed overall response rate:''' 51.6%
| |
| * '''Peritoneal mesothelioma cohort (8 patients):''' 75% ORR, 100% disease control rate
| |
| * '''Median exposure:''' 16.0 months (95% CI 8.1-19.5)
| |
| * '''Median follow-up:''' 19.3 months
| |
| * '''Safety:''' 93.5% experienced grade 3/4 adverse events; no treatment-related deaths
| |
| | |
| Phase 3 trial planning is underway (NCT07133750 registered July 2025).
| |
| | |
| === UV1 Vaccine Plus Checkpoint Inhibitors ===
| |
| | |
| The NIPU trial (Phase II, NCT04300244) demonstrated statistically significant survival improvement when UV1 telomerase vaccine was added to nivolumab plus ipilimumab.<ref>[https://clinicaltrials.gov/study/NCT04300244 UV1 Vaccine With Nivolumab and Ipilimumab in Mesothelioma], ClinicalTrials.gov</ref>
| |
| | |
| '''Results (118 patients randomized):'''
| |
| * '''Median overall survival:''' 15.4 months with UV1 versus 11.1 months without—statistically significant
| |
| * '''Median progression-free survival:''' 4.2 months versus 2.9 months
| |
| * '''Objective response rate:''' 31% versus 16%
| |
| * '''Safety:''' Comparable adverse event rates between groups
| |
| * '''Regulatory Status:''' FDA Fast Track Designation granted February 2024
| |
| | |
| == What Are the Eligibility Requirements for Most Trials? ==
| |
| | |
| === Performance Status Requirements ===
| |
| | |
| Most mesothelioma clinical trials require patients to meet specific baseline criteria. The National Cancer Institute provides guidance on understanding clinical trial eligibility.<ref>[https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/help Finding Clinical Trials], National Cancer Institute</ref>
| |
| | |
| '''ECOG Performance Status:'''
| |
| * '''ECOG 0:''' Fully active, able to carry on all pre-disease activities without restriction
| |
| * '''ECOG 1:''' Restricted in physically strenuous activity but ambulatory and able to carry out light work
| |
| * '''ECOG 2:''' Some trials accept for exceptional cases
| |
| * '''Alternative measure:''' Karnofsky score 70% or higher
| |
| | |
| === Typical Laboratory Value Requirements ===
| |
| | |
| * Absolute neutrophil count 1,500/μL or higher
| |
| * Platelet count 100,000/μL or higher
| |
| * Hemoglobin 9.0 g/dL or higher
| |
| * Creatinine clearance 45 mL/min or higher
| |
| * Bilirubin 1.5x upper limit of normal or lower
| |
| | |
| === Disease Requirements ===
| |
| | |
| * Histologically confirmed mesothelioma (pathology report required)
| |
| * Measurable disease by modified RECIST criteria
| |
| * No untreated brain metastases
| |
| * Specific histology requirements vary by trial
| |
| * Some trials require specific biomarker expression (mesothelin greater than 50% for certain CAR-T trials)
| |
| | |
| {| style="width:100%; background:#fff3cd; border:1px solid #ffc107; border-left:5px solid #ffc107; border-radius:4px; margin:1em 0;"
| |
| |-
| |
| | style="padding:15px; color:#856404;" | '''⚠️ Important:''' Eligibility requirements vary significantly between trials. A patient who does not qualify for one trial may be eligible for others. Work with a mesothelioma specialist to identify all available options.
| |
| |}
| |
| | |
| == Where Are Major Clinical Trials Located? ==
| |
| | |
| === National Cancer Institute (Bethesda, Maryland) ===
| |
| * TNhYP218 CAR-T trial (NCT06885697)
| |
| * Multiple additional mesothelioma studies
| |
| * Travel assistance programs available
| |
| * Contact: NCI Cancer Information Service 1-800-4-CANCER<ref>[https://www.cancer.gov/about-nci/organization/ccct Clinical Center at NIH], National Cancer Institute</ref>
| |
| | |
| === MD Anderson Cancer Center (Houston, Texas) ===
| |
| * 16+ active mesothelioma trials
| |
| * VT3989 TEAD inhibitor trial (lead investigator: Dr. Timothy Yap)
| |
| * Specialized mesothelioma program
| |
| * Telemedicine consultations offered<ref>[https://www.mdanderson.org/cancer-types/mesothelioma.html Mesothelioma Treatment at MD Anderson], MD Anderson Cancer Center</ref>
| |
| | |
| === Memorial Sloan Kettering Cancer Center (New York) ===
| |
| * Intrapleural CAR-T program (NCT04577326)
| |
| * International patient services
| |
| * Dedicated mesothelioma team<ref>[https://www.mskcc.org/cancer-care/types/mesothelioma Mesothelioma at Memorial Sloan Kettering], Memorial Sloan Kettering Cancer Center</ref>
| |
| | |
| === University of Chicago ===
| |
| * ISM6331 trial site
| |
| * ICARuS II peritoneal trial (NCT06057935)
| |
| * Multiple systemic therapy trials
| |
| | |
| === Princess Margaret Cancer Centre (Toronto) ===
| |
| * SMARTER trial headquarters
| |
| * International enrollment accepted
| |
| * Modified surgical protocols
| |
| | |
| == What Are the Financial Considerations for Trial Participation? ==
| |
| | |
| === Costs Covered by Trial Sponsors ===
| |
| * Study drug or intervention
| |
| * Trial-specific tests and procedures
| |
| * Additional monitoring visits required by protocol
| |
| * Some travel expenses (varies by trial)
| |
| | |
| === Patient/Insurance Responsibility ===
| |
| * Standard of care treatments
| |
| * Routine doctor visits
| |
| * Hospital stays if not trial-related
| |
| * Most travel and lodging expenses
| |
| | |
| === Insurance Coverage ===
| |
| | |
| The Affordable Care Act requires most health plans to cover routine patient costs in clinical trials.<ref>[https://www.va.gov/health-care/about-va-health-benefits/va-health-care-and-other-insurance/ VA Health Care and Insurance], U.S. Department of Veterans Affairs</ref>
| |
| | |
| * '''Medicare:''' Covers qualifying trials for Medicare beneficiaries
| |
| * '''Private insurance:''' 44 states require coverage; check your state's mandates
| |
| * '''Medicaid:''' Coverage depends on state regulations
| |
| * '''VA benefits:''' VA covers trial participation at approved facilities for eligible veterans
| |
| | |
| {| style="width:90%; margin:1.5em auto; background:#f8f9fa; border-left:4px solid #1a5276; border-radius:0 4px 4px 0;"
| |
| |-
| |
| | style="padding:20px 25px 15px; font-style:italic; font-size:1.05em; line-height:1.6;" | "Many families don't realize that pursuing legal compensation and participating in clinical trials can happen simultaneously. The two processes are completely separate, and pursuing one doesn't affect the other. We help families navigate both paths at once."
| |
| |-
| |
| | style="padding:5px 25px 20px; text-align:right;" | '''— Michelle Whitman,''' Attorney, Danziger & De Llano
| |
| |}
| |
| | |
| == What Survival Outcomes Can Patients Expect? ==
| |
| | |
| === Current Survival Data by Treatment Type ===
| |
| | |
| {| class="wikitable" style="width:100%; margin:1em 0; border-collapse:collapse;"
| |
| |-
| |
| ! style="background:#1a5276; color:white; padding:12px; text-align:left;" | Treatment Approach
| |
| ! style="background:#1a5276; color:white; padding:12px; text-align:left;" | Median Overall Survival
| |
| ! style="background:#1a5276; color:white; padding:12px; text-align:left;" | Notable Outcomes
| |
| |-
| |
| | style="padding:12px; font-weight:bold; background:#e8f4f8;" | Pembrolizumab + Chemotherapy
| |
| | style="padding:12px; background:#e8f4f8;" | 16.9 months
| |
| | style="padding:12px; background:#e8f4f8;" | FDA approved September 2024; 52% response rate
| |
| |-
| |
| | style="padding:12px; font-weight:bold;" | Nivolumab + Ipilimumab
| |
| | style="padding:12px;" | 18.1 months
| |
| | style="padding:12px;" | 23.2% three-year survival
| |
| |-
| |
| | style="padding:12px; font-weight:bold; background:#e8f4f8;" | MSK Intrapleural CAR-T
| |
| | style="padding:12px; background:#e8f4f8;" | Data maturing
| |
| | style="padding:12px; background:#e8f4f8;" | 83% one-year survival
| |
| |-
| |
| | style="padding:12px; font-weight:bold;" | VT3989 (Relapsed)
| |
| | style="padding:12px;" | Data maturing
| |
| | style="padding:12px;" | 10 months PFS; 32% response rate
| |
| |-
| |
| | style="padding:12px; font-weight:bold; background:#e8f4f8;" | CRS-HIPEC (Peritoneal)
| |
| | style="padding:12px; background:#e8f4f8;" | 53 months
| |
| | style="padding:12px; background:#e8f4f8;" | 47% five-year survival
| |
| |}
| |
| | |
| <ref>[https://mesothelioma.net/multimodal-therapy/ Multimodal Therapy for Mesothelioma], Mesothelioma.net</ref>
| |
| | |
| == What Trials Are Expected in 2026? ==
| |
| | |
| === Confirmed Q1-Q2 2026 Trial Openings ===
| |
| | |
| '''VT3989 Phase III:'''
| |
| * First registrational trial of a TEAD inhibitor in mesothelioma
| |
| * Based on ESMO 2025 data showing 32% ORR
| |
| * Third-line indication<ref>[https://mesotheliomaattorney.com/mesothelioma/treatment/best-centers/ Top Mesothelioma Treatment Centers], MesotheliomaAttorney.com</ref>
| |
| | |
| '''BNT327/PM8002 Phase III:'''
| |
| * NCT07133750 registered July 2025
| |
| * Building on exceptional Phase 2 results
| |
| | |
| '''ISM6331 US Enrollment:'''
| |
| * Expected to open following January 2025 China enrollment
| |
| * First AI-designed mesothelioma drug
| |
| | |
| '''MVdeltaC First-in-Human:'''
| |
| * Measles virus-based immunotherapy
| |
| * FDA Orphan Drug Designation June 2025
| |
| * Clinical trial planned for 2026
| |
| | |
| === Pipeline Developments ===
| |
| | |
| '''Antibody-Drug Conjugates (ADCs):'''
| |
| * SGN-MesoC2 recruiting (updated November 2025)
| |
| * Rinatabart Sesutecan (GEN1184/PRO1184) recruiting (updated December 2025)<ref>[https://mesothelioma.net/latest-mesothelioma-research/ Latest Mesothelioma Research], Mesothelioma.net</ref>
| |
| | |
| == How Do I Find and Enroll in a Clinical Trial? ==
| |
| | |
| === Primary Trial Resources ===
| |
| | |
| * '''ClinicalTrials.gov:''' Official NIH database with all registered trials<ref>[https://clinicaltrials.gov/search?cond=Mesothelioma Search Mesothelioma Trials], ClinicalTrials.gov</ref>
| |
| * '''NCI Cancer Information Service:''' 1-800-4-CANCER
| |
| * '''EmergingMed Navigator:''' Free matching service
| |
| * '''Lazarex Cancer Foundation:''' Financial assistance for trial costs<ref>[https://mesothelioma.net/clinical-trials-for-mesothelioma-treatment-what-to-expect/ Clinical Trials for Mesothelioma], Mesothelioma.net</ref>
| |
| | |
| === Questions to Ask Before Enrolling ===
| |
| | |
| # What phase is the trial? (Phase I = safety focus, Phase II = efficacy, Phase III = comparison)
| |
| # What are the specific eligibility requirements?
| |
| # How many visits are required and where?
| |
| # What costs will I be responsible for?
| |
| # Can I leave the trial if needed?
| |
| # How will this affect my other treatment options?
| |
| # What are the known risks and potential benefits?
| |
| # What happens if the treatment works—can I continue receiving it?
| |
| | |
| {| style="width:90%; margin:1.5em auto; background:#f8f9fa; border-left:4px solid #1a5276; border-radius:0 4px 4px 0;"
| |
| |-
| |
| | style="padding:20px 25px 15px; font-style:italic; font-size:1.05em; line-height:1.6;" | "When my father was diagnosed with mesothelioma, we didn't know about clinical trials or the compensation available to us. Now I help families understand all their options—both medical and legal—so they can make informed decisions during an incredibly difficult time."
| |
| |-
| |
| | style="padding:5px 25px 20px; text-align:right;" | '''— David Foster,''' Client Advocate, Danziger & De Llano
| |
| |}
| |
| | |
| == Key NCT Numbers for Trial Verification ==
| |
| | |
| {| class="wikitable" style="width:100%; margin:1em 0;"
| |
| |-
| |
| ! style="background:#1a5276; color:white; padding:10px;" | Trial Name
| |
| ! style="background:#1a5276; color:white; padding:10px;" | NCT Number
| |
| ! style="background:#1a5276; color:white; padding:10px;" | Status
| |
| |-
| |
| | eVOLVE-Meso (Volrustomig) || [https://clinicaltrials.gov/study/NCT06097728 NCT06097728] || Recruiting
| |
| |-
| |
| | TNhYP218 CAR-T (NCI) || [https://clinicaltrials.gov/study/NCT06885697 NCT06885697] || Recruiting
| |
| |-
| |
| | ISM6331 TEAD Inhibitor || [https://clinicaltrials.gov/study/NCT06566079 NCT06566079] || Recruiting
| |
| |-
| |
| | MSK Intrapleural CAR-T || [https://clinicaltrials.gov/study/NCT04577326 NCT04577326] || Recruiting
| |
| |-
| |
| | SynKIR-110 || [https://clinicaltrials.gov/study/NCT05568680 NCT05568680] || Recruiting
| |
| |-
| |
| | ICARuS II (Peritoneal) || [https://clinicaltrials.gov/study/NCT06057935 NCT06057935] || Recruiting
| |
| |-
| |
| | NERO (Niraparib) || [https://clinicaltrials.gov/study/NCT05455424 NCT05455424] || Completed
| |
| |-
| |
| | NIPU (UV1 Vaccine) || [https://clinicaltrials.gov/study/NCT04300244 NCT04300244] || Completed
| |
| |}
| |
| | |
| <ref>[https://www.mesotheliomalawyercenter.org/mesothelioma-lawyer/ Mesothelioma Lawyers], Mesothelioma Lawyer Center</ref>
| |
| | |
| == Getting Legal Help During Trial Participation ==
| |
| | |
| Patients participating in clinical trials can simultaneously pursue legal compensation from asbestos trust funds and responsible companies. This compensation is entirely separate from trial participation and can help cover expenses not covered by the trial, including travel, lodging, lost wages, and care for family members.<ref>[https://dandell.com/settlements/ Mesothelioma Settlements], Danziger & De Llano</ref>
| |
| | |
| {| style="width:100%; background:linear-gradient(135deg, #e65c00 0%, #f9a825 100%); border-radius:8px; margin:1.5em 0;"
| |
| |-
| |
| | style="padding:25px; text-align:center;" |
| |
| <span style="color:white; font-size:1.3em; font-weight:bold;">🛡️ Free Clinical Trial & Compensation Consultation</span>
| |
| | |
| <span style="color:white; font-size:1.1em;">Our team helps families navigate both treatment options and legal rights.</span>
| |
| | |
| '''[https://dandell.com/contact-us/ <span style="background:white; color:#e65c00; padding:12px 30px; border-radius:5px; font-weight:bold; display:inline-block; margin-top:15px;">Call (866) 222-9990 →</span>]'''
| |
| |}
| |
| | |
| == Related Resources ==
| |
| | |
| * [[Asbestos Trust Funds]] — Access $30+ billion in asbestos trust fund compensation
| |
| * [[Veterans Benefits]] — Veterans disability claims and healthcare coverage
| |
| * [[Choosing a Mesothelioma Attorney]] — What to look for in mesothelioma legal representation
| |
| * [[Mesothelioma Treatment Centers]] — Specialized mesothelioma treatment facilities nationwide
| |
| * [[Understanding Your Diagnosis]] — Medical information for newly diagnosed patients
| |
| | |
| == References ==
| |
| | |
| <references />
| |
| | |
| [[Category:Clinical Trials]]
| |
| [[Category:Mesothelioma Treatment]]
| |
| [[Category:Immunotherapy]]
| |
| [[Category:CAR-T Cell Therapy]]
| |
| [[Category:Targeted Therapy]]
| |
